Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomised, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-line Therapy in Patients With Advanced Gastric Cancer
Brief Summary: This study will compare treatment with bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin, as first-line therapy in patients with locally advanced or metastatic gastric cancer who had not received prior chemotherapy for advanced or metastatic disease.


Options:
A: Arm Label: Everolimus + BSC; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Best Supportive Care (BSC) | Arm Label: Placebo + BSC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Everolimus placebo, Drug: Best Supportive Care (BSC) | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus + BSC | Intervention Type: DRUG; Name: Everolimus placebo; Assigned to Arm(s): Placebo + BSC | Intervention Type: DRUG; Name: Best Supportive Care (BSC); Assigned to Arm(s): Everolimus + BSC, Placebo + BSC
B: Arm Label: Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Capecitabine, Drug: Cisplatin, Drug: 5-fluorouracil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Cisplatin, Drug: Placebo, Drug: 5-fluorouracil | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Bevacizumab, Placebo | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Bevacizumab, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: 5-fluorouracil; Assigned to Arm(s): Bevacizumab, Placebo
C: Arm Label: 1- Docetaxel plus Oxaliplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Drug: oxaliplatin | Arm Label: 2- Docetaxel plus oxaliplatin plus cetuximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Drug: cetuximab, Drug: oxaliplatin | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): 1- Docetaxel plus Oxaliplatin, 2- Docetaxel plus oxaliplatin plus cetuximab | Intervention Type: DRUG; Name: cetuximab; Assigned to Arm(s): 2- Docetaxel plus oxaliplatin plus cetuximab | Intervention Type: DRUG; Name: oxaliplatin; Assigned to Arm(s): 1- Docetaxel plus Oxaliplatin, 2- Docetaxel plus oxaliplatin plus cetuximab
D: Arm Label: Rilotumumab; Type: EXPERIMENTAL; Interventions: Drug: Rilotumumab, Drug: Epirubicin, Drug: Cisplatin, Drug: Capecitabine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, Drug: Epirubicin, Drug: Cisplatin, Drug: Capecitabine | Intervention Type: DRUG; Name: Rilotumumab; Assigned to Arm(s): Rilotumumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): Placebo, Rilotumumab | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Placebo, Rilotumumab | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Placebo, Rilotumumab

Answer: B